First testosterone patch to combat the menopause is developed and inventors say it may boost women’s libido
The world’s first testosterone patch for women with menopausal symptoms is being developed by British researchers.
Medherant is aiming to start clinical trials in the autumn. If the treatment gets regulatory approval, it would be the only testosterone replacement patch available globally and would be introduced first in the UK.
The founder of Medherant, University of Warwick professor David Haddleton, said the potential to improve women’s lives by helping them with their loss of sex drive was ‘huge’.
Women seeking treatment for the effects of menopause on libido currently cannot be prescribed testosterone on the NHS.
Some resort to irregular doses of gel approved only for use on men, experts say.
Medherant is aiming to start clinical trials in the autumn. If the treatment gets regulatory approval, it would be the only testosterone replacement patch available globally and would be introduced first in the UK (file image)
Testosterone is an essential hormone for women and its production drops heavily after menopause.
Although oestrogen and progesterone hormone replacement therapy (HRT) patches – which stick to the skin to deliver medications – are available, there is no testosterone delivery patch for women suffering adverse menopausal symptoms.
Professor Haddleton said: ‘This is a very exciting development for us – the potential of this technology to improve women’s lives is huge.
‘The work we’re doing at Medherant and at Warwick isn’t just theoretical, but instead aimed at a problem women are facing which can drastically affect their everyday lives and jobs.
‘This could deliver a product that is much needed and is just not available.
‘With the technology already proven to work, we can use our new patch to remove needless misery from women’s daily lives.
‘We hope this will transform life for women suffering from post-menopause issues nationally and indeed globally.’
Since 2015, guidelines issued by the National Institute for Health and Care Excellence have recommended that testosterone supplementation be considered for menopausal women with low sexual desire if HRT is not effective.
The new patch is intended to address this gap in menopause products, providing treatment specifically for women that can be made widely available.
Last summer the Daily Mail’s HRT campaign secured a major victory after pharmacists were allowed to prescribe alternatives to out-of-stock hormone replacement therapy treatments.